Booster dose of vaccine COVAXIN® (BBV152) has generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) Variants of SARS-CoV-2 using a live virus neutralization assay. 1. 100%
COVAXIN (BBV152) booster dose study shows promising results. The phase 2, double-blind, randomised controlled COVAXIN® trial demonstrated long-term safety with no serious adverse events. 6 months after receipt of
Bharat Biotech’s COVAXIN® authorized for emergency use by the World Health Organization. The WHO’s Emergency Use Listing (EUL) for COVAXIN® facilitates countries to expedite their regulatory approval processes to introduce
Covaxin phase-3 clinical trials begins at Vydehi Institute of Medical Sciences and Research Centre in Bengaluru. CM Yediyurappa launches the phase-3 trials of Covaxin developed by the Hyderabad-based Bharat Biotech.
